News
XNCR
19.02
+3.54%
0.65
Weekly Report: what happened at XNCR last week (0415-0419)?
Weekly Report · 2d ago
Xencor Becomes Oversold (XNCR)
NASDAQ · 04/16 20:26
Analyst Scoreboard: 6 Ratings For Xencor
Xencor (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company. The company focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics. In the last three months, 6 analysts have released ratings for Xencor. Xencor has an average 12-month price target of $35.33.
Benzinga · 04/16 18:02
Xencor Price Target Cut to $38.00/Share From $56.00 by BTIG
Dow Jones · 04/16 16:15
Xencor Is Maintained at Buy by BTIG
Dow Jones · 04/16 16:15
BTIG Maintains Buy on Xencor, Lowers Price Target to $38
Benzinga · 04/16 16:04
XENCOR INC <XNCR.O>: BTIG CUTS TARGET PRICE TO $38 FROM $56
Reuters · 04/16 05:49
Weekly Report: what happened at XNCR last week (0408-0412)?
Weekly Report · 04/15 10:13
Xencor Appoints Bart Cornelissen As CFO
NASDAQ · 04/09 12:37
Xencor Inc Announces CFO Transition and Executive Compensation Plan
TipRanks · 04/09 12:32
Xencor names Bart Cornelissen to CFO
Xencor names Bart Cornelissen to CFO and senior vice president. He has more than two decades of experience in corporate financial planning, analysis and transaction support. Xencor, Inc. (XNCR) stock is up 2% in pre-market trading.
Seeking Alpha · 04/09 12:17
Xencor Names Bart Cornelissen Chief Financial Officer
Xencor says Bart Cornelissen most recently served as vice president of corporate finance at Seagen. Pfizer acquired Seagen last year in a $43 billion deal. The biopharmaceutical company Xencor has hired him as senior vice president and chief financial officer.
Dow Jones · 04/09 12:17
*Xencor Appoints Bart Cornelissen As Chief Financial Officer >XNCR
Dow Jones · 04/09 12:01
Weekly Report: what happened at XNCR last week (0401-0405)?
Weekly Report · 04/08 10:16
Weekly Report: what happened at XNCR last week (0325-0329)?
Weekly Report · 04/01 10:15
Weekly Report: what happened at XNCR last week (0318-0322)?
Weekly Report · 03/25 10:17
Weekly Report: what happened at XNCR last week (0311-0315)?
Weekly Report · 03/18 10:16
Xencor: Report of proposed sale of securities
Press release · 03/11 20:12
Weekly Report: what happened at XNCR last week (0304-0308)?
Weekly Report · 03/11 10:14
Xencor: Statement of changes in beneficial ownership of securities
Press release · 03/07 22:43
More
Webull provides a variety of real-time XNCR stock news. You can receive the latest news about Xencor through multiple platforms. This information may help you make smarter investment decisions.
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.